v3.26.1
Related Parties Transactions - Schedule of Related Parties Transactions (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Schedule of Related Parties Transactions [Line Items]          
Interest expense – related parties $ 42,270 $ 36,264 $ 83,766 $ 77,392  
Operating sublease income – related parties 23,207 17,400 41,207 34,800  
Accrued interest payable to ABVC 667,613   667,613   $ 583,847
ABVC [Member]          
Schedule of Related Parties Transactions [Line Items]          
Interest expense – related parties 42,270 36,264 83,766 77,392  
Operating sublease income – related parties 3,000 2,400 6,000 4,800  
Due to related parties [1] 4,363,201   4,363,201   4,089,971
AiBtl [Member]          
Schedule of Related Parties Transactions [Line Items]          
Operating sublease income – related parties 3,000 3,000 6,000 6,000  
Due from related parties 12,558   12,558   24,558
Due to related parties 18,000   18,000  
Related Party [Member]          
Schedule of Related Parties Transactions [Line Items]          
Operating sublease income – related parties 6,000 $ 5,400 12,000 $ 10,800  
Due to related parties 4,630,269   4,630,269   4,298,769
BioLite [Member]          
Schedule of Related Parties Transactions [Line Items]          
Due to related parties [2] 211,068   211,068   208,798
Management [Member]          
Schedule of Related Parties Transactions [Line Items]          
Due to related parties [3] 38,000   38,000  
Accrued interest payable to ABVC [Member]          
Schedule of Related Parties Transactions [Line Items]          
Accrued interest payable to ABVC [1] $ 667,613   $ 667,613   $ 583,847
ABVC BioPharma, Inc. (“ABVC”) [Member]          
Schedule of Related Parties Transactions [Line Items]          
Relationship with the Company and its subsidiaries     Sole shareholder of BioKey Cayman    
BioLite Inc. (“BioLite”) [Member]          
Schedule of Related Parties Transactions [Line Items]          
Relationship with the Company and its subsidiaries     A majority owned subsidiary of ABVC    
AiBtloPharma Inc. (“AiBtl”) [Member]          
Schedule of Related Parties Transactions [Line Items]          
Relationship with the Company and its subsidiaries     A majority owned subsidiary of ABVC    
Rgene Corporation (the “Rgene”) [Member]          
Schedule of Related Parties Transactions [Line Items]          
Relationship with the Company and its subsidiaries     The Chairman of Rgene is Mr. Tsung-Shann Jiang    
The Jiangs [Member]          
Schedule of Related Parties Transactions [Line Items]          
Relationship with the Company and its subsidiaries     Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of Rgene, the Chief Scientific Officer (CSO) of ABVC, the Chairman and CEO of BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst   Ms. Shu-Ling Jiang, a member of board of directors of ABVC and BioLite Inc.    
[1]

Since 2020, the Company has been relying on ABVC’s recurring loans to support the Company’s operation. These loans bore an interest rate of 1.5% to 6.5% per annum. As of June 30, 2026 and December 31, 2025, the loan principal amounted to $2,665,911 and $2,629,911, respectively.

 

The remaining balances are accrued interest and operating expenses paid by ABVC on behalf of the Company. This amount is due and payable upon demand by ABVC.
[2] Mainly payables to clinical development services, offsetting by certain payments made by the Company on behalf of BioLite. The advances bear no interest.
[3] In June 2026, management of Biokey advanced $38,000 to Biokey for working capital purposes. The advances bear an interest rate of 3.75% per annum, starting from June 3, 2026 for 6 months.